NASDAQ:NTUS

Natus Medical Competitors

$27.08
-0.99 (-3.53 %)
(As of 04/20/2021 12:58 PM ET)
Add
Compare
Today's Range
$27.04
Now: $27.08
$28.13
50-Day Range
$23.95
MA: $26.06
$28.63
52-Week Range
$16.38
Now: $27.08
$28.83
Volume6,632 shs
Average Volume185,310 shs
Market Capitalization$917.31 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72

Competitors

Natus Medical (NASDAQ:NTUS) Vs. CNMD, INMD, OM, BLFS, AXGN, and TMDX

Should you be buying NTUS stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Natus Medical, including CONMED (CNMD), InMode (INMD), Outset Medical (OM), BioLife Solutions (BLFS), AxoGen (AXGN), and TransMedics Group (TMDX).

CONMED (NYSE:CNMD) and Natus Medical (NASDAQ:NTUS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Volatility & Risk

CONMED has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Insider & Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Comparatively, 1.5% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares CONMED and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED0.04%9.48%3.75%
Natus Medical-4.33%3.87%2.50%

Analyst Recommendations

This is a summary of current ratings and target prices for CONMED and Natus Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED02302.60
Natus Medical01002.00

CONMED currently has a consensus target price of $103.25, suggesting a potential downside of 18.70%. Given CONMED's stronger consensus rating and higher probable upside, equities analysts clearly believe CONMED is more favorable than Natus Medical.

Valuation & Earnings

This table compares CONMED and Natus Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million3.87$28.62 million$2.6448.10
Natus Medical$495.52 million1.85$-15,670,000.00$1.2421.84

CONMED has higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Summary

CONMED beats Natus Medical on 12 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and InMode (NASDAQ:INMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Earnings and Valuation

This table compares Natus Medical and InMode's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.85$-15,670,000.00$1.2421.84
InMode$156.36 million17.13$61.15 million$1.6052.36

InMode has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Natus Medical and InMode, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
InMode00403.00

InMode has a consensus target price of $71.50, indicating a potential downside of 13.96%. Given InMode's stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than Natus Medical.

Insider and Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Natus Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.

Profitability

This table compares Natus Medical and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
InMode32.57%28.56%24.14%

Summary

InMode beats Natus Medical on 11 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Natus Medical and Outset Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
Outset Medical03502.63

Outset Medical has a consensus price target of $57.80, suggesting a potential upside of 7.70%. Given Outset Medical's stronger consensus rating and higher probable upside, analysts plainly believe Outset Medical is more favorable than Natus Medical.

Insider and Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 84.6% of Outset Medical shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Natus Medical and Outset Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.85$-15,670,000.00$1.2421.84
Outset MedicalN/AN/AN/AN/AN/A

Outset Medical has lower revenue, but higher earnings than Natus Medical.

Profitability

This table compares Natus Medical and Outset Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
Outset MedicalN/AN/AN/A

Summary

Natus Medical beats Outset Medical on 5 of the 9 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Profitability

This table compares BioLife Solutions and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
Natus Medical-4.33%3.87%2.50%

Analyst Ratings

This is a summary of current ratings and recommmendations for BioLife Solutions and Natus Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions01902.90
Natus Medical01002.00

BioLife Solutions presently has a consensus price target of $46.6667, indicating a potential upside of 49.05%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than Natus Medical.

Earnings and Valuation

This table compares BioLife Solutions and Natus Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million38.59$-1,660,000.00$0.08395.25
Natus Medical$495.52 million1.85$-15,670,000.00$1.2421.84

BioLife Solutions has higher earnings, but lower revenue than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 89.7% of Natus Medical shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by insiders. Comparatively, 1.5% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

BioLife Solutions beats Natus Medical on 9 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for AxoGen and Natus Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
Natus Medical01002.00

AxoGen presently has a consensus target price of $23.75, suggesting a potential upside of 33.88%. Given AxoGen's stronger consensus rating and higher possible upside, equities analysts clearly believe AxoGen is more favorable than Natus Medical.

Profitability

This table compares AxoGen and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
Natus Medical-4.33%3.87%2.50%

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Earnings & Valuation

This table compares AxoGen and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.00$-29,140,000.00($0.68)-26.96
Natus Medical$495.52 million1.85$-15,670,000.00$1.2421.84

Natus Medical has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 89.7% of Natus Medical shares are owned by institutional investors. 6.9% of AxoGen shares are owned by insiders. Comparatively, 1.5% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Natus Medical beats AxoGen on 8 of the 14 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 89.7% of Natus Medical shares are held by institutional investors. 13.1% of TransMedics Group shares are held by company insiders. Comparatively, 1.5% of Natus Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares TransMedics Group and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million28.94$-33,550,000.00($2.36)-10.57
Natus Medical$495.52 million1.85$-15,670,000.00$1.2421.84

Natus Medical has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TransMedics Group and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
Natus Medical-4.33%3.87%2.50%

Analyst Recommendations

This is a breakdown of recent ratings for TransMedics Group and Natus Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
Natus Medical01002.00

TransMedics Group currently has a consensus target price of $44.20, indicating a potential upside of 79.82%. Given TransMedics Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe TransMedics Group is more favorable than Natus Medical.

Volatility & Risk

TransMedics Group has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.


Natus Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CONMED logo
CNMD
CONMED
1.6$126.98-2.3%$3.78 billion$955.10 million-3,174.50Analyst Revision
News Coverage
InMode logo
INMD
InMode
1.5$83.77-2.7%$2.75 billion$156.36 million60.27
Outset Medical logo
OM
Outset Medical
1.1$53.79-0.1%$2.31 billionN/A0.00Analyst Report
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$31.62-3.4%$1.09 billion$27.37 million-43.31Insider Selling
Increase in Short Interest
AxoGen logo
AXGN
AxoGen
1.7$18.33-2.9%$725.74 million$106.71 million-29.10News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$24.95-4.2%$711.89 million$23.60 million-17.82Increase in Short Interest
ViewRay logo
VRAY
ViewRay
1.5$3.90-6.9%$670.54 million$87.78 million-4.38News Coverage
Gap Up
Zynex logo
ZYXI
Zynex
1.8$14.66-5.8%$540.60 million$45.47 million44.42News Coverage
Cutera logo
CUTR
Cutera
1.3$27.62-5.0%$515.89 million$181.71 million-15.26News Coverage
Edap Tms logo
EDAP
Edap Tms
1.3$8.28-2.8%$248.00 million$50.23 million-138.00Increase in Short Interest
Gap Down
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.11-1.8%$194.80 million$3.38 million-3.72Decrease in Short Interest
FONR
FONAR
1.1$17.64-1.5%$117.38 million$85.69 million16.64
IRIDEX logo
IRIX
IRIDEX
0.9$7.05-5.2%$115.17 million$43.45 million-12.82Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.54-0.6%$113.17 millionN/A0.00
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.19-4.6%$95.26 million$10,000.00-1.19Analyst Downgrade
Gap Up
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.13-4.4%$94.07 millionN/A-1.49Analyst Downgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.76-5.4%$89.68 million$2.39 million-2.22Gap Down
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$17.11-1.1%$39.98 million$1.50 million-0.98
CHF Solutions logo
CHFS
CHF Solutions
1.7$4.98-6.4%$32.00 million$5.51 million-0.10Increase in Short Interest
News Coverage
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.47-3.6%$26.48 million$6.57 million-0.01
Star Equity logo
STRR
Star Equity
0.1$2.72-2.2%$13.09 million$114.18 million-0.87
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.